Jong Chul Park, Medical Oncologist at Massachusetts General Hospital, shared a post on LinkedIn:
“A really unique symposium bridging translational science and clinical research.
It was great to see the work of young scientists, and I especially enjoyed the multi-D panel discussions on the challenges and future directions of contemporary neoadjuvant trials in light of the recent KEYNOTE-689 success (and limitations).
Appreciate the organizers for the kind invitation and the opportunity to share my work.”
Other articles about Head and Neck Cancer on OncoDaily.